These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 2636648)

  • 1. Long-term efficacy and safety of oral calcium as compared to A1(OH)3 as phosphate binders.
    Moriniere P; Hocine C; Boudailliez B; Belbrik S; Renaud H; Westeel PF; Solal MC; Fournier A
    Kidney Int Suppl; 1989 Nov; 27():S133-5. PubMed ID: 2636648
    [No Abstract]   [Full Text] [Related]  

  • 2. [Magnesium hydroxide treatment of hyperphosphatemia in chronic hemodialysis patients with an aluminum overload].
    Roujouleh H; Lavaud S; Toupance O; Melin JP; Chanard J
    Nephrologie; 1987; 8(2):45-50. PubMed ID: 3614505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Features of correction of phosphate-calcium metabolism disorders in terminal renal failure].
    Pilotovich VS; Romanovich VP; Shilaĭ LM; Tukaĭ NN
    Klin Med (Mosk); 1992; 70(3-4):49-51. PubMed ID: 1507848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Value of Maalox in the treatment of eso-gastro-duodenal inflammatory and ulcerative diseases].
    Pillegand B; Rumeau JM; Hessel L; Croguennec B
    Med Chir Dig; 1977; 6(8):575-7. PubMed ID: 611345
    [No Abstract]   [Full Text] [Related]  

  • 6. Prevention of osteitis fibrosa, aluminium bone disease and soft-tissue calcification in dialysis patients: a long-term comparison of moderate doses of oral calcium +/- Mg(OH)2 vs Al(OH)3 +/- 1 alpha OH vitamin D3.
    Morinière P; Boudailliez B; Hocine C; Belbrik S; Renaud H; Westeel PF; Solal MC; Fournier A
    Nephrol Dial Transplant; 1989; 4(12):1045-53. PubMed ID: 2517325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Considerations on antacid therapy].
    Holtermüller KH; Bohlen E; Castro M; Weis HJ
    Med Klin; 1977 Jul; 72(30):1229-41. PubMed ID: 329089
    [No Abstract]   [Full Text] [Related]  

  • 8. Antacid-induced hypophosphatemia: an unusual cause of "pseudo-myopathy".
    Searles RP; Bankhurst AD; Ahlin TD; Messner RP
    J Rheumatol; 1977; 4(2):176-8. PubMed ID: 881694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.
    Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP
    Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of orally administered aluminium hydroxide and results of withdrawal.
    Bournerias F; Monnier N; Reveillaud RJ
    Proc Eur Dial Transplant Assoc; 1983; 20():207-12. PubMed ID: 6657657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Aluminum and magnesium burden of dialysis patients using antacids. A comparative study].
    Eichhorn M
    Fortschr Med; 1989 Aug; 107(23):502-6. PubMed ID: 2670719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absence of in vivo and in vitro interactions of an aluminum hydroxide, magnesium hydroxide containing antacid with cimetidine in patients with peptic ulcer.
    Allgayer H; Röllinghoff W; Paumgartner G
    Z Gastroenterol; 1983 Jul; 21(7):351-4. PubMed ID: 6613216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Aluminum poisoning by phosphate binders in kidney insufficiency].
    Fuchs C; Dorn D; Doht B; Freytag E; Fuchs CA; Henning HV; Scheler F
    Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():1313-5. PubMed ID: 611842
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-term use of magnesium hydroxide as a phosphate binder in patients on hemodialysis.
    Oe PL; Lips P; van der Meulen J; de Vries PM; van Bronswijk H; Donker AJ
    Clin Nephrol; 1987 Oct; 28(4):180-5. PubMed ID: 3690899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Osteomalacia and severe backache as a complication of long-term intake of Novalucol].
    Fredstorp L; Eyrich R
    Lakartidningen; 1984 Feb; 81(5):359-60. PubMed ID: 6230495
    [No Abstract]   [Full Text] [Related]  

  • 16. [Phosphate binders for therapy of hyperphosphatemia causing secondary hyperparathyroidism and renal osteodystrophy in patients with chronic renal failure].
    Kanagawa S; Yosikawa Y; Dohi Y
    Nihon Rinsho; 1991 Dec; 49 Suppl():770-4. PubMed ID: 1808348
    [No Abstract]   [Full Text] [Related]  

  • 17. [Iatrogenic aluminum osteopathy in a uremic infant].
    Koch H; Reich H; Franke D; Delling G
    Monatsschr Kinderheilkd; 1986 May; 134(5):279-81. PubMed ID: 3724766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical effect of a highly concentrated calcium dialysate--with special emphasis on reversible calcinosis cutis].
    Hirano H; Satoo M; Fueki H; Arakawa M
    Nihon Rinsho; 1975 Feb; 33(2):442-7. PubMed ID: 1170392
    [No Abstract]   [Full Text] [Related]  

  • 19. Tumorous paraarticular calcifications due to undigested phosphate-binders in a patient undergoing regular hemodialysis.
    Kovarik J; Frühwald F; Seidl G; Woliszczuk W; Pinggera WF
    Clin Nephrol; 1984 Feb; 21(2):141-2. PubMed ID: 6723115
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders.
    Sturtevant JM; Hawley CM; Reiger K; Johnson DW; Campbell SB; Burke JR; Bofinger A; Isbel NM
    Nephrology (Carlton); 2004 Dec; 9(6):406-13. PubMed ID: 15663645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.